The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta caused its own stock to drop during the gene therapy maker’s safety troubles ...

Two complementary studies led by researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS ...